Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

Ole De Backer; Lars Søndergaard

doi:10.3389/fcvm.2018.00045

Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

Ole De Backer, Lars Søndergaard

Institut for Klinisk Medicin

5 Citationer (Scopus)

25 Downloads (Pure)

Abstract

The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

Originalsprog	Engelsk
Artikelnummer	45
Tidsskrift	Frontiers in Cardiovascular Medicine
Vol/bind	5
Antal sider	4
ISSN	2297-055X
DOI	https://doi.org/10.3389/fcvm.2018.00045
Status	Udgivet - 11 maj 2018

Adgang til dokumentet

10.3389/fcvm.2018.00045Licens: CC BY

Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger PatientsForlagets udgivne version, 265 KBLicens: CC BY

Citationsformater

@article{877432964dee486bbcbc5e1f91d8f248,

title = "Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients",

abstract = "The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.",

author = "{De Backer}, Ole and Lars S{\o}ndergaard",

year = "2018",

month = may,

day = "11",

doi = "10.3389/fcvm.2018.00045",

language = "English",

volume = "5",

journal = "Frontiers in Cardiovascular Medicine",

issn = "2297-055X",

publisher = "Frontiers Media",

}

TY - JOUR

T1 - Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

AU - De Backer, Ole

AU - Søndergaard, Lars

PY - 2018/5/11

Y1 - 2018/5/11

N2 - The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

AB - The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

U2 - 10.3389/fcvm.2018.00045

DO - 10.3389/fcvm.2018.00045

M3 - Journal article

C2 - 29868611

SN - 2297-055X

VL - 5

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

M1 - 45

ER -

Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater